ReviewWorld journal of gastroenterology2016
Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 159 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Silymarin® - Efficacy in Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) Controlled by Laboratory and and Elastographic Parameters
Effect of Very Low-calorie Diet on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and Non-alcoholic Fatty Liver Disease
The Clock Thickens: Morning or Evening Training for the Treatment of NAFLD? (TikTac Study)
Who cites it
159 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effects of glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide on liver stiffness and steatosis evaluated through FibroscanInternal and emergency medicine · 2026Pooled it
- EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Obesity facts · 2024Guideline
- Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.Diabetes, obesity & metabolism · 2021Pooled it
- Choline and betaine concentrations in plasma discriminate levels of dietary choline intake in healthy adults: analysis of a double-blind randomized crossover controlled feeding study.The American journal of clinical nutrition · 2026Trial
- The Usefulness of Metformin and Ganwei for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized, Placebo-Controlled Trial.International journal of molecular sciences · 2026Trial
- Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial.Scientific reports · 2022Trial
- Trial
- EUS-Guided Shear Wave Elastography in a Real-World Cohort: Diagnostic Accuracy and the Impact of Measurement Variability.Digestive diseases and sciences · 2026Article
- Risk factors associated with adverse metabolic health in youth with perinatally acquired HIV living in the United Kingdom.AIDS (London, England) · 2026Observational
- Liver fibrosis risk: a silent threat in type 1 diabetes mellitus.Journal of endocrinological investigation · 2026Article
- Egyptian MASLD genetic map; between the leading TM6SF2 gene and role of epigenetic.Journal of applied genetics · 2026Article
- Prevalence and Risk Factors of Gallbladder Polyps Among Jeju Natives and Migrants: Retrospective Cross-Sectional Study.Journal of clinical medicine · 2026Article
- A novel serum metabolite classifier for identifying Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) integrating metabolomics and machine learning.BMC gastroenterology · 2026Article
- Large Language Models can Identify the Presence of MASH and Extract VCTE Measurements from Unstructured Documentation.Digestive diseases and sciences · 2026Article
- Thermoacoustic Ultrasound Assessment of Liver Steatosis-A Novel Approach for MASLD Diagnosis.Diagnostics (Basel, Switzerland) · 2026Article
- From MASLD to MELD 3.0: Integrating the Spectrum of Liver Disease Risk Stratification into Primary Care.The Eurasian journal of medicine · 2026Article
- Diagnosis and grading of steatotic liver disease via clinical and laboratory data using machine learning.Scientific reports · 2026Article
- Not always autoimmune hepatitis: Hepatic steatosis is associated with autoantibodies positivity in patients with hepatocellular dysfunction.World journal of hepatology · 2026Article
- Discriminative performance of non-invasive scoring systems for VCTE-defined steatosis and fibrosis in patients with psoriasis.Hepatology forum · 2026Article
- Aspirin Use Does Not Significantly Reduce the Risk of Liver Fibrosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.Food science & nutrition · 2026Article
99 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Currently, the routinely used modalities are unable to adequately determine the levels of steatosis and fibrosis (laboratory tests and ultrasonography) or cannot be applied as a screening procedure (liver biopsy). Among the non-invasive tests, transient elastography (FibroScan(®), TE) with controlled attenuation parameter (CAP) has demonstrated good accuracy in quantifying the levels of liver steatosis and fibrosis in patients with NAFLD, the factors associated with the diagnosis and NAFLD progression. The method is fast, reliable and reproducible, with good intra- and interobserver levels of agreement, thus allowing for population-wide screening and disease follow-up. The initial inability of the procedure to accurately determine fibrosis and steatosis in obese patients has been addressed with the development of the obese-specific XL probe. TE with CAP is a viable alternative to ultrasonography, both as an initial assessment and during follow-up of patients with NAFLD. Its ability to exclude patients with advanced fibrosis may be used to identify low-risk NAFLD patients in whom liver biopsy is not needed, therefore reducing the risk of complications and the financial costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.